SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease
NCT ID: NCT07011979
Last Updated: 2025-06-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2022-01-07
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question it aims to answer is:
What are the risk factors for developing Inflammatory Bowel Disease?
Researchers will compare groups at high risk for IBD to healthy populations and to patients already diagnosed with IBD.
Participants will
* undergo assessments of general demographic and clinical characteristics.
* be monitored for symptoms using questionnaires administered at regular intervals.
* have blood tests and stool examinations performed. In cases where participants undergo colonoscopy for routine clinical indications, gut biopsies will also be performed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research for the Precision Medicine in the Treatment of Inflammatory Bowel Disease
NCT07166588
Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk
NCT02193464
Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Korea
NCT02229344
A Prospective Study on the Incidence and Risk Factors Related to Infection in Patients With Inflammatory Bowel Disease
NCT02904590
Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
NCT03264690
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Blood and stools will be used for genomic and proteomic, metabolomic analysis. 16s rRNA gene sequencing and whole genome shotgun sequencing will be done for microbiome analysis. Biopsy specimen will be used for proteomic analysis.
Adverse events related with blood sampling will be monitored in outpatient clinic.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients who are diagnosed with autoimmune diseases
* patients with functional gastrointestinal disorders who are ASCA-positive
Exclusion Criteria
* Treatment history of Diabetes Mellitus, Irritable Bowel Syndrome, or colon cancer.
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SeongJoon Koh
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-2110-155-1266
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.